The rate of complications after endoscopic biliary sphincterotomy can vary widely in different circumstances and is primarily related to the indication for the procedure and to endoscopic technique, rather than to the age or general medical condition of the patients.

These data support the concept of a dose-response effect for cytarabine in patients with AML who are 60 years of age or younger. The results with the high-dose schedule in this age group are comparable to those reported in similar patients who have undergone allogeneic bone marrow transplantation during a first remission.

Acute myeloid leukemia (AML) remains the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML provide recommendations on the diagnostic evaluation and workup for AML, risk assessment based on cytogenetic and molecular features, treatment options for induction and consolidation therapies for younger and older (age ≥ 65 years) adult patients, and key supportive care considerations.

In many cell systems the interaction of ligands with their receptors causes rapid breakdown and resynthesis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). Recent work has focused on the role of the degradation products of PtdIns(4,5)P2 as intermediates in the activation of cell function and growth: inositol trisphosphate (InsP3) can release Ca2+ from intracellular stores and diacylglycerol is thought to activate protein kinase C. This enzyme is also activated by phorbol esters (for example, 12-O-tetradecanoyl phorbol 13-acetate, TPA) and this is assumed to account for the pleiotropic effects of TPA on cell function and growth. Mouse thymocytes are not mitogenically stimulated by TPA alone, but it is a potent co-mitogen in combination with either concanavalin A (Con A) or A23187 (A. N. Corps and J.C.M., unpublished observations). Here we show that mitogenic concentrations of TPA, A23187 and Con A each cause an increase in the net phosphorylation of phosphatidylinositol (PtdIns) to PtdIns(4,5)P2 in mouse thymocytes. This is consistent with simulation by the mitogens of the same phosphoinositide phosphorylations in intact cells as recently demonstrated for the isolated products of the src and ros viral oncogenes in a cell-free system.

Combined treatment with infused PSC 833 and DNR is well tolerated and has activity in patients with poor risk acute myeloid leukemia. Administration of PSC 833 delays elimination of daunorubicinol, but yields variable changes in DNR systemic exposure.